WS Investor
04 Nov 2026, 14:41
CVS Health Plunges 12.5% Despite Higher Guidance as Medical Cost Concerns Persist
CVS Health (NYSE: CVS) shares fell about 12.5% after the company reported stronger third-quarter earnings and raised its full-year outlook, but maintained a cautious view on elevated medical cost trends and potential macroeconomic headwinds.
Third-quarter revenue increased 5.4% year over year to $108.4 billion. Adjusted EPS rose to $2.09 from $1.60, while adjusted operating income increased 21.2% across the company’s operating segments.
The Health Care Benefits segment showed meaningful improvement. Adjusted operating income climbed to $912 million from $314 million, while the medical benefit ratio improved to 91.3% from 92.8%. CVS attributed the improvement mainly to stronger underlying performance in its government business.
Health Services revenue rose 9.5% to $54.0 billion, while adjusted operating income increased 2.7% to $2.11 billion. Pharmacy & Consumer Wellness revenue fell 2.0% to $35.5 billion, but adjusted operating income increased 10.6% to $1.64 billion, supported by core pharmacy strength and contributions from Rite Aid asset acquisitions.
CVS raised its 2026 adjusted EPS guidance to at least $8.20 from a previous range of $7.90-$8.10. GAAP EPS guidance was increased to at least $6.98, while operating cash flow guidance rose sharply to at least $15.5 billion from at least $11.5 billion. :chatgpt-content-reference{index="6"}
However, management also said it remains cautious for the rest of the year because of continued elevated cost trends and possible macroeconomic pressures.
The sharp 12.5% decline suggests investors are looking beyond the headline guidance increase and focusing on the durability of the margin recovery in CVS’s insurance business. The medical benefit ratio improved materially, but it remains elevated, while the company’s explicit warning on cost trends may be raising concerns that recent earnings improvement could prove harder to sustain than the stronger quarterly numbers imply.
CVS Health (NYSE: CVS) shares fell about 12.5% after the company reported stronger third-quarter earnings and raised its full-year outlook, but maintained a cautious view on elevated medical cost trends and potential macroeconomic headwinds.
Third-quarter revenue increased 5.4% year over year to $108.4 billion. Adjusted EPS rose to $2.09 from $1.60, while adjusted operating income increased 21.2% across the company’s operating segments.
The Health Care Benefits segment showed meaningful improvement. Adjusted operating income climbed to $912 million from $314 million, while the medical benefit ratio improved to 91.3% from 92.8%. CVS attributed the improvement mainly to stronger underlying performance in its government business.
Health Services revenue rose 9.5% to $54.0 billion, while adjusted operating income increased 2.7% to $2.11 billion. Pharmacy & Consumer Wellness revenue fell 2.0% to $35.5 billion, but adjusted operating income increased 10.6% to $1.64 billion, supported by core pharmacy strength and contributions from Rite Aid asset acquisitions.
CVS raised its 2026 adjusted EPS guidance to at least $8.20 from a previous range of $7.90-$8.10. GAAP EPS guidance was increased to at least $6.98, while operating cash flow guidance rose sharply to at least $15.5 billion from at least $11.5 billion. :chatgpt-content-reference{index="6"}
However, management also said it remains cautious for the rest of the year because of continued elevated cost trends and possible macroeconomic pressures.
The sharp 12.5% decline suggests investors are looking beyond the headline guidance increase and focusing on the durability of the margin recovery in CVS’s insurance business. The medical benefit ratio improved materially, but it remains elevated, while the company’s explicit warning on cost trends may be raising concerns that recent earnings improvement could prove harder to sustain than the stronger quarterly numbers imply.
